This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Antman, E. M. Search for Related Content PubMed PubMed Citation Articles by Antman, E. M. Related Collections Cardiovascular Pharmacology Coagulation Thrombin Heparin Other anticoagulants Acute coronary syndromes Acute myocardial infarction Coagulation and fibronolysis

(Circulation. 2001;103:2310.)
© 2001 American Heart Association, Inc.

Cardiovascular Drugs

The Search for Replacements for Unfractionated Heparin

Elliott M. Antman, MD

From the Cardiovascular Division, Brigham and Women’s Hospital, Boston, Mass.

Correspondence to Elliott M. Antman, MD, Cardiovascular Division, Brigham and Women’s Hospital, 75 Francis St, Boston, MA 02115. E-mail eantman@rics.bwh.harvard.edu

	Introduction

 
Antithrombotic therapy is central to the management of patients presenting with an acute coronary syndrome (ACS). In addition to powerful new antiplatelet therapies, multiple agents capable of inhibiting thrombin are now available to clinicians (Figure).

View larger version (98K): [in this window] [in a new window]   Figure 1. Activated coagulation cascade and platelet aggregation in patients with an ACS. A, With disruption of a vulnerable plaque, tissue factor (TF) is exposed and ultimately complexes with activated factor VII (VIIa). TF:VIIa complex converts factor X to its active form (Xa). Through a multiplier effect, a single molecule of factor Xa leads to downstream production of many molecules of thrombin through its participation in prothrombinase complex along with factor V and calcium (Ca++) on a phospholipid surface, such as membrane of activated platelets (Plt). Thrombin is a potent agonist for platelet activation via binding to thrombin receptor on platelets. Aggregates of platelets are formed by cross-bridging via attachments of ligands such as fibrinogen (FGN) to the GP IIb/IIIa receptors on adjacent platelets. B, Sites of action of antithrombin and antiplatelet agents. Relative strength of actions at various positions is shown semiquantitatively by size of font in diagram. Thus, UFH has similar inhibitory action against thrombin and factor Xa, whereas LMWH has greater relative inhibitory capacity against factor Xa than thrombin. Direct antithrombins have little effect on generation of thrombin but are potent inhibitors of thrombin that has been formed. In contrast, TFPI and related compounds act more proximally in coagulation cascade to inhibit formation of factor Xa and limit downstream production of thrombin. . . . [Full Text of this Article]

This article has been cited by other articles:

				R. Dumaine, M. Borentain, O. Bertel, C. Bode, R. Gallo, H. D. White, J.-P. Collet, S. R. Steinhubl, and G. Montalescot Intravenous Low-Molecular-Weight Heparins Compared With Unfractionated Heparin in Percutaneous Coronary Intervention: Quantitative Review of Randomized Trials Arch Intern Med, December 10, 2007; 167(22): 2423 - 2430. [Abstract] [Full Text] [PDF]

				S. A. Murphy, C. M. Gibson, D. A. Morrow, F. Van de Werf, I. B. Menown, S. G. Goodman, K. W. Mahaffey, M. Cohen, C. H. McCabe, E. M. Antman, et al. Efficacy and safety of the low-molecular weight heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum: a meta-analysis Eur. Heart J., September 1, 2007; 28(17): 2077 - 2086. [Abstract] [Full Text] [PDF]

				M. S. Sabatine, D. A. Morrow, A. Dalby, M. Pfisterer, T. Duris, J. Lopez-Sendon, S. A. Murphy, R. Gao, E. M. Antman, E. Braunwald, et al. Efficacy and Safety of Enoxaparin Versus Unfractionated Heparin in Patients With ST-Segment Elevation Myocardial Infarction Also Treated With Clopidogrel J. Am. Coll. Cardiol., June 12, 2007; 49(23): 2256 - 2263. [Abstract] [Full Text] [PDF]

				C. M. Gibson, S. A. Murphy, G. Montalescot, D. A. Morrow, D. Ardissino, M. Cohen, D. C. Gulba, O. H. Kracoff, B. S. Lewis, N. Roguin, et al. Percutaneous Coronary Intervention in Patients Receiving Enoxaparin or Unfractionated Heparin After Fibrinolytic Therapy for ST-Segment Elevation Myocardial Infarction in the ExTRACT-TIMI 25 Trial J. Am. Coll. Cardiol., June 12, 2007; 49(23): 2238 - 2246. [Abstract] [Full Text] [PDF]

				R. De Caterina, S. Husted, L. Wallentin, G. Agnelli, F. Bachmann, C. Baigent, J. Jespersen, S. D. Kristensen, G. Montalescot, A. Siegbahn, et al. Anticoagulants in heart disease: current status and perspectives Eur. Heart J., April 10, 2007; (2007) ehl492v1. [Full Text] [PDF]

				E. M. Antman, D. A. Morrow, C. H. McCabe, S. A. Murphy, M. Ruda, Z. Sadowski, A. Budaj, J. L. Lopez-Sendon, S. Guneri, F. Jiang, et al. Enoxaparin versus Unfractionated Heparin with Fibrinolysis for ST-Elevation Myocardial Infarction N. Engl. J. Med., April 6, 2006; 354(14): 1477 - 1488. [Abstract] [Full Text] [PDF]

				M. S. Sabatine, D. A. Morrow, G. Montalescot, M. Dellborg, J. L. Leiva-Pons, M. Keltai, S. A. Murphy, C. H. McCabe, C. M. Gibson, C. P. Cannon, et al. Angiographic and Clinical Outcomes in Patients Receiving Low-Molecular-Weight Heparin Versus Unfractionated Heparin in ST-Elevation Myocardial Infarction Treated With Fibrinolytics in the CLARITY-TIMI 28 Trial Circulation, December 20, 2005; 112(25): 3846 - 3854. [Abstract] [Full Text] [PDF]

				G. C. Wong, R. P. Giugliano, and E. M. Antman Use of Low-Molecular-Weight Heparins in the Management of Acute Coronary Artery Syndromes and Percutaneous Coronary Intervention JAMA, January 15, 2003; 289(3): 331 - 342. [Abstract] [Full Text] [PDF]

				G Niccoli and A P Banning Heparin dose during percutaneous coronary intervention: how low dare we go? Heart, October 1, 2002; 88(4): 331 - 334. [Abstract] [Full Text] [PDF]

				R. M. Califf and D. L. DeMets Principles From Clinical Trials Relevant to Clinical Practice: Part I Circulation, August 20, 2002; 106(8): 1015 - 1021. [Full Text] [PDF]

				D.A. Vorchheimer and V. Fuster Thrombin inhibitors in acute coronary artery disease Eur. Heart J., August 1, 2002; 23(15): 1142 - 1144. [Full Text] [PDF]

				E. M. Antman, H. W. Louwerenburg, H. F. Baars, J. C.L. Wesdorp, B. Hamer, J.-P. Bassand, F. Bigonzi, G. Pisapia, C. M. Gibson, H. Heidbuchel, et al. Enoxaparin as Adjunctive Antithrombin Therapy for ST-Elevation Myocardial Infarction: Results of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) 23 Trial Circulation, April 9, 2002; 105(14): 1642 - 1649. [Abstract] [Full Text] [PDF]